In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib (PBD) or lenalidomide (PLD) in multiple myeloma

Enrique M. Ocio,1,2 David Vilanova,1 Peter Atadja,3 Patricia Maiso,1 Edvan Crusoe,1,4 Diego Fernández-Lázaro,1 Mercedes Garayoa,1 Laura San-Segundo,4 Teresa Hernández-Iglesias,1 Enrique de Álava,1 Wenlin Shao,2 Yun-gmae Yao,3 Atanasio Pandiella,1 and Jesús F. San-Miguel1,2

1 Centro de Investigación del Cáncer, IIBMCC/CSIC-Universidad de Salamanca, Spain; 2 Department of Hematology, University Hospital of Salamanca, Salamanca, Spain, and 3 Novartis Institutes for Biomedical Research, Cambridge, MA, USA


©2009 Ferrata Storti Foundation. This is an open-access paper.

Supplementary Table 1. Genes specifically deregulated by the triple combinations of PBD. MM1S cells were treated with panobinostat (7 nM), dexamethasone (0.9 µM) and bortezomib (3 nM) as single agents for 48 hours and in triple combinations for 24 hour, in order to obtain 20-25% apoptosis. After this period, cells were collected and changes in GEP were analyzed. A summary of the most relevant genes specifically deregulated by the triple combination, grouped by categories is shown.

Supplementary Table 2. Genes specifically deregulated by the triple combinations of PLD. MM1S cells were treated with panobinostat (7 nM), dexamethasone (0.9 µM) and lenalidomide (1 µM) as single agents for 48 hours and in triple combinations for 26 hours, in order to obtain 20-25% apoptosis. After this period, cells were collected and changes in GEP were analyzed. A summary of the most relevant genes specifically deregulated by the triple combination, grouped by categories, is shown.